Theravance Biopharma (TBPH) Enterprise Value (2014 - 2026)
Theravance Biopharma (TBPH) posted quarterly Enterprise Value of -$394.7 million for Q1 2026, down 201.61% year-over-year from $388.4 million in Q1 2025, and down 25.15% quarter-over-quarter from -$315.4 million in Q4 2025.
Theravance Biopharma (TBPH) Enterprise Value (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Enterprise Value for 13 consecutive years, with -$394.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 201.61% year-over-year to -$394.7 million; the TTM figure through Mar 2026 stood at -$394.7 million (down 201.61% YoY), while the FY2025 annual figure was -$315.4 million, down 256.94% from the prior year.
- Enterprise Value fell to -$394.7 million in Q1 2026 per TBPH's latest filing, from -$315.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$88.4 million in Q4 2024 and bottomed at -$486.8 million in Q3 2022.
- Historically, Enterprise Value has averaged -$213.2 million across 5 years, with a median of -$147.5 million in 2022.
- Annual changes were most pronounced in 2023 — Enterprise Value surged 72.47% — and 2025, when it tumbled 260.85%.
- Theravance Biopharma's Enterprise Value stood at -$327.5 million in 2022, then soared by 68.72% to -$102.4 million in 2023, then climbed by 13.74% to -$88.4 million in 2024, then sank by 256.94% to -$315.4 million in 2025, then decreased by 25.15% to -$394.7 million in 2026.
- Business Quant data shows TBPH's Enterprise Value at -$394.7 million in Q1 2026, -$315.4 million in Q4 2025, and -$329.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | -387.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -387.66 Mn |
| Mar 31, 2026 | -394.67 Mn |
| Dec 31, 2025 | -315.36 Mn |
| Sep 30, 2025 | -329.68 Mn |
| Jun 30, 2025 | -338.80 Mn |
| Mar 31, 2025 | -130.86 Mn |
| Dec 31, 2024 | -88.35 Mn |
| Sep 30, 2024 | -91.36 Mn |
| Jun 30, 2024 | -96.08 Mn |
| Mar 31, 2024 | -99.98 Mn |
| Dec 31, 2023 | -102.43 Mn |
| Sep 30, 2023 | -134.00 Mn |
| Jun 30, 2023 | -167.45 Mn |
| Mar 31, 2023 | -241.26 Mn |
| Dec 31, 2022 | -327.48 Mn |
| Sep 30, 2022 | -486.83 Mn |
| Jun 30, 2022 | -132.85 Mn |
| Mar 31, 2022 | -147.52 Mn |
| Dec 31, 2021 | -173.47 Mn |
| Sep 30, 2021 | -216.21 Mn |